SELECT MEDICAL HOLDINGS CORP (SEM)

Sector: Health Care

    Home/Companies/SEM/Annual Meeting

2026 Annual Meeting Analysis

SELECT MEDICAL HOLDINGS CORP · Meeting: April 23, 2026

Policy v1.0high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

3

Directors AGAINST

0

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Class II Directors

3 FOR
✓ FOR
Robert A. Ortenzio

Long-tenured director (since 2005) and co-founder serving as Executive Chairman; SEM's 3-year stock return of +27.0% outperforms the IHF benchmark by +34.3 percentage points, well below the 65pp threshold required to trigger a vote against under the strong-positive-TSR tier; no overboarding, attendance, or independence issues identified.

✓ FOR
Daniel J. Thomas

Director since July 2019 with deep healthcare industry experience including former CEO roles; TSR trigger does not apply given SEM's +34.3pp outperformance of IHF (threshold is 65pp); no overboarding, attendance, or independence concerns identified.

✓ FOR
Parvinderjit S. Khanuja

Director since November 2021 with relevant medical and healthcare operations expertise; TSR trigger does not apply given SEM's strong outperformance of IHF; no overboarding, attendance, or independence concerns identified.

All three Class II nominees pass the policy screens: SEM's 3-year stock return of +27.0% outperforms the IHF — iShares U.S. Healthcare Providers ETF benchmark by +34.3 percentage points, which does not meet the 65pp threshold needed to trigger a vote against under the strong-positive-TSR tier. No overboarding, attendance failures, or independence issues were identified for any nominee. The board discloses a skills matrix. Vote FOR all three nominees.

Say on Pay

✓ FOR

CEO

Thomas P. Mullin

Total Comp

$3,042,527

Prior Support

91%%

time based equity only

CEO Thomas P. Mullin's total compensation of $3,042,527 — comprising $618,000 base salary, $939,360 performance bonus, and $1,425,000 in restricted stock awards, plus $60,167 in other compensation — is modest for a CEO at a $2B healthcare company and appears within a reasonable benchmark range. The annual bonus plan ties payouts to pre-set earnings-per-share and return-on-equity targets, and for 2025 the company achieved $1.16 EPS and 8.6% return on equity, resulting in bonuses at 190% of target, which is consistent with genuine above-target performance. The main structural concern is that equity awards use only time-based vesting with no performance conditions, which the Compensation Committee justifies by citing the heavily regulated Medicare reimbursement environment; this is a mild negative factor but is offset by the fact that a significant portion of total pay is tied to the performance-based annual bonus. Prior shareholder support was a strong 91% and the overall pay level is not excessive.

Auditor Ratification

✓ FOR

Auditor

PricewaterhouseCoopers LLP

Tenure

N/A

Audit Fees

$2,645,000

Non-Audit Fees

$2,120

Non-audit fees (all other fees of $2,120) represent less than 1% of audit fees ($2,645,000), far below the 50% threshold that would raise independence concerns. PwC is a Big 4 firm appropriate for a company of SEM's size. Auditor tenure is not disclosed in the proxy, so the tenure trigger does not apply per policy. No material restatements were identified.

Stockholder Proposals

3 proposals submitted by shareholders

Proposal 4

Approval of an Amendment to the Company's Amended and Restated Certificate of Incorporation to Phase Out the Classified Structure of the Board

✓ FOR
Filed by:Board of Directors (company proposal)OtherCharter Amendment
Board recommends: FOR
pro-shareholder governance improvementboard declassification phased over three years to 2028

This is a board-initiated charter amendment that would eliminate the current three-class staggered board structure over a three-year transition period, resulting in all directors standing for annual election by 2028. Moving from a classified to a declassified board is a mainstream, widely supported governance improvement that increases director accountability to shareholders. The phased approach is reasonable and standard for declassification transitions. Vote FOR.

Proposal 5

Company Proposal – Provide Stockholders the Right to Call a Special Meeting of Stockholders at a 25% Ownership Threshold

✓ FOR
Filed by:Board of Directors (company proposal)OtherGovernance
Board recommends: FOR
grants shareholders new right to call special meetings25% threshold is market-standard

This board-sponsored proposal would give shareholders owning at least 25% of outstanding shares the right to call a special meeting — a right shareholders currently do not have at all. Granting shareholders the ability to call special meetings is a pro-shareholder governance improvement. A 25% threshold is broadly considered market-standard and provides meaningful access to shareholders with significant stakes while protecting against abuse by very small holders. Vote FOR.

Proposal 6

Stockholder Proposal – Provide Stockholders the Right to Call a Special Meeting of Stockholders at a 10% Ownership Threshold

✓ FOR
Filed by:Stockholder proponent (identity not specified in extracted filing text)OtherGovernance
Board recommends: AGAINST
governance improvementlower threshold increases shareholder accesscompany is simultaneously granting 25% right via Proposal 5

This stockholder proposal asks the company to allow shareholders owning as little as 10% of shares to call a special meeting, compared to the 25% threshold proposed by the board in Proposal 5. A lower threshold gives more shareholders — including medium-sized institutional holders — the practical ability to call a meeting, which is a stronger shareholder right. While the 25% threshold in Proposal 5 is an improvement over the current status quo of no right at all, a 10% threshold is more consistent with best-practice governance standards and does not present a meaningful risk of abuse. Because both proposals are advisory, supporting this proposal is a reasonable signal to the board that shareholders favor broader access. Vote FOR.

Overall Assessment

The 2026 Select Medical Holdings annual meeting presents a generally shareholder-friendly ballot: the company is voluntarily declassifying its board, granting shareholders the right to call special meetings, and the executive pay program reflects genuine pay-for-performance linkage with modest CEO compensation relative to the company's size. The primary compensation concern — equity awards vesting purely on time rather than performance — is noted but not disqualifying given the strong bonus plan structure and 91% prior shareholder approval of pay.

Filing date: March 4, 2026·Policy v1.0·high confidence